Successful Portfolios LLC Purchases 3,267 Shares of Pfizer Inc. (NYSE:PFE)

Successful Portfolios LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 26.6% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 15,560 shares of the biopharmaceutical company’s stock after buying an additional 3,267 shares during the quarter. Successful Portfolios LLC’s holdings in Pfizer were worth $448,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Worth Asset Management LLC purchased a new stake in Pfizer in the 1st quarter worth about $29,000. Briaud Financial Planning Inc purchased a new position in shares of Pfizer in the third quarter worth about $30,000. Sanctuary Wealth Management L.L.C. bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $50,000. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer during the 3rd quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC boosted its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of a number of analyst reports. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Friday, March 1st. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Finally, Truist Financial lowered their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Trading Up 0.7 %

Shares of NYSE:PFE traded up $0.18 on Wednesday, reaching $27.77. 34,187,438 shares of the company traded hands, compared to its average volume of 43,897,863. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The business’s 50-day simple moving average is $27.47 and its 200 day simple moving average is $29.47. The stock has a market capitalization of $157.25 billion, a P/E ratio of 77.17, a price-to-earnings-growth ratio of 1.23 and a beta of 0.61. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter last year, the business earned $1.14 earnings per share. The business’s revenue was down 41.3% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.